Research
Size:
Share:
Search studies by: All,
Active,
Completed

OMASPECT – Sponsored by Hoffmann-La Roche

Completed Study | Duration: 96 weeks

OMASPECT was a multicenter, open-label extension study for the treatment of age-related macular degeneration (AMD). This study evaluated the long-term safety and... View study

LADDER - Sponsored by Roche/Genenthech

Completed Study | Duration: 38 weeks

LADDER was a multicenter, randomized, active-treatment controlled Phase II clinical trial for the treatment of wet AMD that evaluated the safety and efficacy of the... View study

ONYX – Sponsored by Regeneron Pharmaceuticals, Inc.

Completed Study | Duration: 36 weeks

ONYX REGN910-3 was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It... View study

OHR-1601 – Sponsored by Ohr Pharmaceuticals, Inc.

Completed Study | Duration: 24 months

OHR-1601 was a multi-center, randomized, and double-masked Phase III clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the... View study

CAPELLA – Sponsored by Regeneron Pharmaceuticals, Inc.

Completed Study | Duration: 52 weeks

CAPELLA was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the... View study

AVENUE – Sponsored by Hoffman-La Roche

Completed Study | Duration: 36 weeks

RO6867461 was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the... View study

CEDAR – Sponsored by Allergan

Completed Study | Duration: 104 weeks

CEDAR was a multi-center, prospective, randomized Phase III clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy... View study

NEUROTECH

Completed Study | Duration: 24 Months

Phase II NEUROTECH was a multi-center, prospective, randomized clinical trial for the treatment of recurrent subfoveal choroidal neovascularization (CNV) secondary to... View study